{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:47:37Z","timestamp":1777506457406,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ejphar.2016.04.033","type":"journal-article","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T01:25:05Z","timestamp":1462065905000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice"],"prefix":"10.1016","volume":"781","author":[{"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Obniska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Wiklik-Poudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Sa\u0142at","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.04.033_bib1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1248\/bpb.b13-00735","article-title":"Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats","volume":"37","author":"Aoki","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2016.04.033_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2006.04.009","article-title":"Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy","volume":"539","author":"Beyreuther","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2011.05.025","article-title":"Antiepileptic drug therapy: does mechanism of action matter?","volume":"21","author":"Brodie","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejphar.2016.04.033_bib5","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1523\/JNEUROSCI.06-07-02064.1986","article-title":"3H-batrachotoxinin-A benzoate binding to voltage-sensitive sodium channels: inhibition by the channel blockers tetrodotoxin and saxitoxin","volume":"6","author":"Brown","year":"1986","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2016.04.033_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-3565(25)05160-2","article-title":"Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test","volume":"107","author":"Brown","year":"1953","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.04.033_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","article-title":"Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies","volume":"60","author":"Culy","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2016.04.033_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2165\/00023210-200923070-00002","article-title":"Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders","volume":"23","author":"Curia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2016.04.033_bib9","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1016\/j.bmc.2014.07.042","article-title":"Novel fluorinated pyrrolo[1,2-a]pyrazine-2,6-dione derivatives: synthesis and anticonvulsant evaluation in animal models of epilepsy","volume":"22","author":"Dawidowski","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib10","first-page":"91","article-title":"Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy","volume":"106","author":"Dedeurwaerdere","year":"2006","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.ejphar.2016.04.033_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/jps.3030460119","article-title":"The pharmacological activity of a series of basic esters of mono- and dialkylmalonic acids","volume":"46","author":"Dunham","year":"1957","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.ejphar.2016.04.033_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2016.04.033_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pbb.2003.09.019","article-title":"Comparative anticonvulsant activity of N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives in rodents","volume":"77","author":"Ferreri","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2016.04.033_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.bjp.0701320","article-title":"Gabapentin (neurontin) and S-(+)\u22123-isobutylgaba represent a novel class of selective antihyperalgesic agents","volume":"121","author":"Field","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1248\/bpb.32.732","article-title":"Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit","volume":"32","author":"Gauchan","year":"2009","journal-title":"Biol. Pharm. Bull."},{"issue":"11","key":"10.1016\/j.ejphar.2016.04.033_bib16","doi-asserted-by":"crossref","first-page":"e0141221","DOI":"10.1371\/journal.pone.0141221","article-title":"Repeated 6-Hz Corneal Stimulation Progressively Increases FosB\/\u0394FosB Levels in the Lateral Amygdala and Induces Seizure Generalization to the Hippocampus","volume":"10","author":"Giordano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2016.04.033_bib17","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1073\/pnas.79.11.3656","article-title":"[3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists","volume":"79","author":"Gould","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejphar.2016.04.033_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1527-3458.2007.00009.x","article-title":"Ethosuximide: from bench to bedside","volume":"13","author":"G\u00f6ren","year":"2007","journal-title":"CNS Drug. Rev."},{"key":"10.1016\/j.ejphar.2016.04.033_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1472-8206.2009.00801.x","article-title":"Animal models of neuropathic pain","volume":"25","author":"Jaggi","year":"2011","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib20","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.0013-9580.2004.04504.x","article-title":"Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice","volume":"45","author":"Kaminski","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2016.04.033_bib21","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/j.bmc.2015.03.038","article-title":"Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives","volume":"23","author":"Kami\u0144ski","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib22","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1021\/acs.jmedchem.5b00578","article-title":"Design, synthesis and anticonvulsant activity of new hybrid compounds derived from 2-(2,5-dioxopyrrolidin-1-yl)propanamides and 2-(2,5-dioxopyrrolidin-1-yl)butanamides","volume":"58","author":"Kami\u0144ski","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","article-title":"Implications and mechanism of action of gabapentin in neuropathic pain","volume":"36","author":"Kukkar","year":"2013","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1528-1157.2001.0420s4007.x","article-title":"Animal models used in the screening of antiepileptic drugs","volume":"42","author":"Kupferberg","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2016.04.033_bib25","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.04.033_bib26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/epi.12893","article-title":"Genetic background of mice strongly influences treatment resistance in the 6Hz seizure model","volume":"56","author":"Leclercq","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2016.04.033_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuropharm.2008.06.007","article-title":"Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection","volume":"55","author":"Ling","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2016.04.033_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2016.04.033_bib29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0028-3908(02)00400-8","article-title":"Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels","volume":"44","author":"Liu","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2016.04.033_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0920-1211(91)90075-Q","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models","volume":"8","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0920-1211(91)90041-D","article-title":"The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices","volume":"9","author":"L\u00f6scher","year":"1991","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2016.04.033_bib33","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejphar.2016.04.033_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(10)70059-4","article-title":"Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders","volume":"9","author":"Mantegazza","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11940-015-0381-2","article-title":"Treatment of Neuropathic Pain","volume":"17","author":"Mendlik","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib36","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1021\/ja01154a126","article-title":"An investigation of N-R-a-R1-a-phenylsuccinimides","volume":"73","author":"Miller","year":"1951","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejphar.2016.04.033_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pnpbp.2013.08.009","article-title":"Effect of sildenafil, a selective phosphodiesterase 5 inhibitor, on the anticonvulsant action of some antiepileptic drugs in the mouse 6-Hz psychomotor seizure model","volume":"47","author":"Nieoczym","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2016.04.033_bib38","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.bmc.2016.02.026","article-title":"Synthesis, and anticonvulsant activity of new amides derived from 3-methyl- or 3-ethyl-3-methyl-2,5-dioxo-pyrrolidin-1-yl-acetic acids","volume":"24","author":"Obniska","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.07.017","article-title":"Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2,5-dioxo-pyrrolidin-1-yl-acetic acid","volume":"102","author":"Obniska","year":"2015","journal-title":"Eur. J. MEd. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharep.2014.08.002","article-title":"Antinociceptive properties of N-Mannich bases derived from 3-substituted pyrrolidine-2,5-dione in the formalin model of persistent pain in mice","volume":"67","author":"Obniska","year":"2015","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.ejphar.2016.04.033_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib42","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0301-0082(93)90044-S","article-title":"Spatial and temporal aspects of spinal cord and brainstem activation in the formalin pain model","volume":"41","author":"Porro","year":"1993","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00210-015-1194-2","article-title":"Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione","volume":"389","author":"Rapacz","year":"2016","journal-title":"Naunyn Schmiede. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1744-8069-7-29","article-title":"Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice","volume":"7","author":"Renn","year":"2011","journal-title":"Mol. Pain."},{"key":"10.1016\/j.ejphar.2016.04.033_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.eplepsyres.2005.09.012","article-title":"Molecular targets versus models for new antiepileptic drug discovery","volume":"68","author":"Rogawski","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrn1430","article-title":"The neurobiology of antiepileptic drugs","volume":"5","author":"Rogawski","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2016.04.033_bib47","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2016.04.033_bib48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.neuropharm.2003.11.028","article-title":"Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy","volume":"46","author":"Russo","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2016.04.033_bib49","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ardp.201400152","article-title":"Synthesis, physicochemical, and anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl analog","volume":"347","author":"Rybka","year":"2014","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejphar.2016.04.033_bib50","first-page":"1","article-title":"Synthesis and anticonvulsant activity of new N-mannich bases derived from benzhydryl- and isopropyl-pyrrolidine-2,5-dione","author":"Rybka","year":"2015","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.04.033_bib51","doi-asserted-by":"crossref","unstructured":"S., Rybka, J., Obniska, A., Rapacz, A., Furga\u0142a, B., Filipek, P., \u017bmudzki, 2016. Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from 3-(1-phenylethyl)- and 3-benzyl-pyrrolidine-2,5-dione. Bioorg. Med. Chem. Lett. (Epub ahead of print).","DOI":"10.1016\/j.bmcl.2016.03.075"},{"key":"10.1016\/j.ejphar.2016.04.033_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2016.04.033_bib53","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1474-4422(14)70076-6","article-title":"The challenge and promise of anti-epileptic therapy development in animal models","volume":"13","author":"Simonato","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2016.04.033_bib54","series-title":"Molecular and Cellular Targets for Anti-epileptic Drugs","first-page":"191","article-title":"The NIH Anticonvulsant Drug Development (ADD) Program: Preclinical Anticonvulsant Screening Project","author":"Stables","year":"1997"},{"key":"10.1016\/j.ejphar.2016.04.033_bib55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpain.2005.04.002","article-title":"Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain","volume":"10","author":"St\u00f6hr","year":"2006","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejphar.2016.04.033_bib56","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.anes.0000435634.34709.65","article-title":"Characterization of acute and chronic neuropathies induced by oxaliplatin in mice and differential effects of a novel mitochondria-targeted antioxidant on the neuropathies","volume":"120","author":"Toyama","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2016.04.033_bib57","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1523\/JNEUROSCI.08-09-03354.1988","article-title":"Omega-conotoxin GVIA binding to a high-affinity receptor in brain: characterization, calcium sensitivity, and solubilization","volume":"8","author":"Wagner","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2016.04.033_bib58","first-page":"36","article-title":"Discovery and preclinical development of antiepileptic drugs","author":"White","year":"2002"},{"key":"10.1016\/j.ejphar.2016.04.033_bib59","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuroscience.2006.09.044","article-title":"Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit","volume":"144","author":"Xiao","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2016.04.033_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00210-013-0853-4","article-title":"Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties","volume":"386","author":"Ximenes","year":"2013","journal-title":"Naunyn Schmiede. Arch. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916302473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916302473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T23:30:10Z","timestamp":1748907010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916302473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":60,"alternative-id":["S0014299916302473"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.04.033","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}